RENO, Nev., July 30, 2026 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry leader in energy storage and maker of Battle Born Batteries®, today announced that the Company will release its financial and operational results for the second quarter ended June 30, 2026 after market close on Thursday, August 6, 2026. The earnings press release will be followed by a conference call on Thursday, August 6, 2026, at 4:30 PM Eastern Time. Interested investors and other parties may access the live webcast via the link found here or through the Events and Presentations page within the Investor Relations section of Dragonfly Energy’s website at https://investors.dragonflyenergy.com/events-and-presentations/default.aspx. To join by phone and participate in the Q&A, please...

Revenue: $913 million, up 10% year-over-year Net Earnings: $86 million, up 59% year-over-year Adjusted EBITDA: $128 million, up 33% year-over-year Diluted EPS: $0.32, up 60% year-over-year Adjusted Diluted EPS: $0.35, up 52% year-over-year Bookings: $1.1 billion (book-to-bill ratio of 1.2x) Record Funded Backlog: $5.1 billion, up 17% year-over-year Increases 2026 guidance for Adjusted EBITDA and Adjusted Diluted EPS Announced the $450 million acquisition of Raft, expanding DRS’s multi-domain AI, data fusion and mission software capabilities Dividend: Company declares cash dividend of $0.09 per share to be paid on August 27, 2026ARLINGTON, Va., July 30, 2026 (GLOBE NEWSWIRE) — Leonardo DRS, Inc. (Nasdaq: DRS), a leading provider of advanced defense technologies, today reported financial results for the second quarter 2026, which...

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) — SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Thursday, August 6, 2026. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company’s website at http://www.siga.com in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921...

Dosing underway in Phase 2a multidose portion of the INLIGHTTM trial of WVE-007 (INHBE GalNAc-siRNA) in individuals with obesity (BMI: 35-50 kg/m2) and comorbidities; trial will also inform WVE-007’s potential in MASH, type 2 diabetes, and other cardiometabolic diseases Phase 2 combination with incretin and post-incretin maintenance trials of WVE-007 on track to initiate in 2H 2026 FDA meeting scheduled for end of summer 2026 on potential accelerated approval pathway for WVE-006 (GalNAc-RNA editing); data from RestorAATion-2 trial support differentiated therapeutic approach for both lung and liver manifestations of AATD CTA submission for WVE-008 for PNPLA3 liver disease (GalNAc-RNA editing) on track for 2H 2026 Well capitalized with cash, cash equivalents, and marketable securities of $490.6 million as of June 30, 2026 and expected...